Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. News
  7. Summary
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Most relevant news about CELLTRION, INC.
10/06U.S. to invest another $1 bln in rapid COVID-19 tests
RE
09/23Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 P..
CI
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulized Form of ..
CI
06/14Celltrion Rallies After Positive Data on Covid-19 Treatment
DJ
06/13CELLTRION : says trial shows antibody COVID-19 treatment to be safe and effective
RE
06/07Glythera Limited announced that it has received ú34 million in funding from Mirae Asset..
CI
04/29Celltrion, Inc. Receives FDA Emergency Use Authorization for Point of Care Antigen Rapi..
CI
04/01CELLTRION : Healthcare receives positive CHMP opinion for subcutaneous formulation of infl..
AQ
03/03CELLTRION : EMA review of regdanvimab for COVID-19 to support national decisions on early ..
AQ
02/26EU regulator advises use of Regeneron antibody cocktail for COVID-19
RE
02/25CELLTRION : EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19
AQ
02/11Celltrion Develops Tailored Neutralising Antibody Cocktail Treatment with CT-P59 to Tac..
CI
02/05Celltrion’s COVID-19 Treatment Candidate Receives Korean MFDS Conditional Marketing Aut..
CI
02/05Enthusiasm Fades for Covid-19 Antibody Treatments in South Korea
DJ
More most relevant news
All news about CELLTRION, INC.
10/11EU assesses Regeneron/Roche COVID-19 antibody cocktail for authorisation
RE
10/06U.S. to invest another $1 bln in rapid COVID-19 tests
RE
09/23Celltrion Awards Up to $626 Million from the Department of Defense to Supply Covid-19 P..
CI
09/21EU signs joint procurement deal for Eli Lilly COVID-19 treatment
RE
09/20180 LIFE SCIENCES : Plans Supply Deal With Celltrion Healthcare For Anti-TNF Product Trial..
MT
09/17South Korea approves Celltrion's COVID-19 treatment for use
RE
08/13MARKET CHATTER : Brazil Approves Celltrion's COVID-19 Treatment for Emergency Use
MT
08/06MARKET CHATTER : Celltrion, TriLink BioTechnologies Enter Deal to Develop mRNA Vaccine Pla..
MT
08/02MARKET CHATTER : Celltrion Healthcare Secures Orders for Anticancer Biosimilars from Brazi..
MT
07/22Inhalon Biopharma, Inc. Collaborates with Celltrion, Inc. to Develop Nebulized Form of ..
CI
More news
News in other languages on CELLTRION, INC.
10/04COVID : Ema valuta autorizzazione immissione in commercio Regkirona
09/20180 Life Sciences prévoit un accord de fourniture avec Celltrion Healthcare pour les es..
07/20MÄRKTE ASIEN/US-Vorgaben und Konjunktursorgen dämpfen Kauflust
06/15MÄRKTE ASIEN/Uneinheitlich - Sydney und Seoul auf Rekordjagd
06/15MÄRKTE ASIEN/Tokio und Sydney fest - Schanghai und Hongkong leichter
06/14MÄRKTE ASIEN/Tokio freundlich - Rekordhoch in Seoul
05/07VACCINI : Ue; aperti a dialogo, Usa sblocchi export (Stampa)
05/04MÄRKTE ASIEN/Erholt - Steigende Corona-Zahlen belasten in Taiwan
04/19MÄRKTE ASIEN/Überwiegend positive Stimmung an Börsen dank US-Rekorden
04/19MÄRKTE ASIEN/Positive Stimmung an den Börsen dank US-Rekorden
More news
Analyst Recommendations on CELLTRION, INC.
2018Roche steps up efficiency drive to take sting out of biosimilars
RE
2018Upbeat Roche bests rival Novartis as new drugs fuel growth
RE
More recommendations
Press releases
04/01CELLTRION : Healthcare receives positive CHMP opinion for subcutaneous formulation of infl..
AQ
03/03CELLTRION : EMA review of regdanvimab for COVID-19 to support national decisions on early ..
AQ
02/25CELLTRION : EMA starts rolling review of Celltrion antibody regdanvimab for COVID-19
AQ
2020CELLTRION : Phase II trial to study anti-COVID-19 mAb CT-P59 completes enrolment
AQ
2020CELLTRION : COVID-19 antibody treatment to enter Phase III trial
AQ
More press releases
Upcoming event on CELLTRION, INC.